Department of Cardiovascular Disease, Cleveland Clinic, Cleveland, Ohio 44195, USA.
J Am Coll Cardiol. 2010 Feb 9;55(6):579-86. doi: 10.1016/j.jacc.2009.08.070.
This study sought to examine the safety and efficacy of laser-assisted lead extraction and the indications, outcomes, and risk factors in a large series of consecutive patients.
The need for lead extraction has been increasing in direct relationship to the increased numbers of cardiovascular implantable electronic devices.
Consecutive patients undergoing transvenous laser-assisted lead extraction at 13 centers were included.
Between January 2004 and December 2007, 1,449 consecutive patients underwent laser-assisted lead extraction of 2,405 leads (20 to 270 procedures/site). Median implantation duration was 82.1 months (0.4 to 356.8 months). Leads were completely removed 96.5% of the time, with a 97.7% clinical success rate whereby clinical goals associated with the indication for lead removal were achieved. Failure to achieve clinical success was associated with body mass index <25 kg/m(2) and low extraction volume centers. Procedural failure was higher in leads implanted for >10 years and when performed in low volume centers. Major adverse events in 20 patients were directly related to the procedure (1.4%) including 4 deaths (0.28%). Major adverse effects were associated with patients with a body mass index <25 kg/m(2). Overall all-cause in-hospital mortality was 1.86%; 4.3% when associated with endocarditis, 7.9% when associated with endocarditis and diabetes, and 12.4% when associated with endocarditis and creatinine > or =2.0. Indicators of all-cause in-hospital mortality were pocket infections, device-related endocarditis, diabetes, and creatinine > or =2.0.
Lead extraction employing laser sheaths is highly successful with a low procedural complication rate. Total mortality is substantially increased with pocket infections or device-related endocarditis, particularly in the setting of diabetes, renal insufficiency, or body mass index <25 kg/m(2). Centers with smaller case volumes tended to have a lower rate of successful extraction.
本研究旨在探讨激光辅助导线拔除的安全性和有效性,以及在一系列连续患者中适应证、结局和危险因素。
随着心血管植入式电子设备数量的增加,对导线拔除的需求也在不断增加。
在 13 个中心连续纳入接受经静脉激光辅助导线拔除的患者。
2004 年 1 月至 2007 年 12 月,连续 1449 例患者行 2405 根导线(每个部位 20 至 270 次手术)的激光辅助导线拔除术。植入中位时间为 82.1 个月(0.4 至 356.8 个月)。导线完全拔除率为 96.5%,临床成功率为 97.7%,即与导线拔除适应证相关的临床目标得以实现。临床成功率失败与 BMI<25kg/m(2)和低提取量中心相关。植入时间>10 年和在低容量中心进行时,程序失败率较高。20 例患者的 20 例主要不良事件与该程序直接相关(1.4%),包括 4 例死亡(0.28%)。主要不良事件与 BMI<25kg/m(2)的患者相关。总体全因住院死亡率为 1.86%;与心内膜炎相关者为 4.3%,与心内膜炎和糖尿病相关者为 7.9%,与心内膜炎和肌酐≥2.0 相关者为 12.4%。全因住院死亡率的指标为囊袋感染、器械相关心内膜炎、糖尿病和肌酐≥2.0。
采用激光鞘的导线拔除成功率高,并发症发生率低。全因死亡率显著增加与囊袋感染或器械相关心内膜炎,尤其是在糖尿病、肾功能不全或 BMI<25kg/m(2)的情况下。病例量较小的中心,成功拔除的比例较低。